Psoriasis
Retreatment with efalizumab presents efficacious option for psoriasis patients who quit treatment
Published in Drug Week, June 9th, 2006
According to recent research from Canada, "Efalizumab targets T cell-mediated steps important in psoriasis immunopathogenesis. We sought to evaluate the efficacy and safety of efalizumab retreatment in patients with moderate-to-severe plaque psoriasis. In this open-label, phase III study, 365 patients who received efalizumab therapy during an earlier clinical trial were retreated with 12 weeks of subcutaneous efalizumab (1 mg/kg/wk) 35 days or more after their last dose of efalizumab."
"After 12 weeks of...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
Source: Drug Week (2006-06-09)
More Articles from Drug Week
- Drug Development
Anacor presents data on mechanism of action for topical antifungal treatment - Drug Development
Troglitazone induction of COX-2 expression is dependent on ERK activation in keratinocytes - Hepatitis Drug Development
Entecavir demonstrates more viral suppression compared to lamivudine - Leishmania & Tuberculosis Vaccine
Mycobacterial DNA-hsp65 in PLGA microspheres induces protection against L. major infection - Adverse Drug Reaction
Bausch & Lomb responds to U.S. CDC release of data on Fusarium keratitis cases - Allergy & Immunology
Asthma protection is associated with IL-17F sequence variant (His161Arg) - More from this issue of Drug Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
